RBC Capital Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Maintains Target Price $260
Why Inspire Medical Systems (INSP) Is a Top Momentum Stock for the Long-Term
Inspire Medical Systems, Inc. to Report Fourth Quarter and Fiscal 2024 Financial Results on February 10, 2025
BofA Securities Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Maintains Target Price $255
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Denali Therapeutics (DNLI) and Inspire Medical Systems (INSP)
Oppenheimer Maintains Inspire Medical Systems(INSP.US) With Hold Rating
